Ji Z S, Mahley R W
Gladstone Institute of Cardiovascular Disease, Cardiovascular Research Institute, San Francisco, CA 94141-9100.
Arterioscler Thromb. 1994 Dec;14(12):2025-31. doi: 10.1161/01.atv.14.12.2025.
Bovine lactoferrin inhibits the clearance of remnant lipoproteins from the plasma and competes with the cell-surface binding of apolipoprotein (apo) E-enriched remnants. We established that lactoferrin inhibits remnant binding and uptake by interacting with both heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor-related protein (LRP). The binding of 125I-lactoferrin was inhibited 45% to 60% in HepG2 hepatocytes and wild-type Chinese hamster ovary (CHO) cells treated with heparinase to remove HSPG. In mutant CHO cells (pgsD-677) lacking HSPG, the level of 125I-lactoferrin binding was approximately 50% that seen with wild-type CHO cells; thus, about one half of lactoferrin binding appears to be mediated through cell-surface HSPG. A significant fraction of the residual binding of the lactoferrin appears to be mediated through the LRP. The 39-kd protein known to bind to the LRP and to block ligand interaction inhibited 125I-lactoferrin degradation in wild-type CHO cells by 60% to 65%. The addition of the 39-kd protein plus heparinase treatment reduced the binding by 85% to 90% (this combination blocks direct interaction with both the LRP and HSPG). However, it was also shown that the 39-kd protein bound to HSPG and the LRP. Heparinase treatment of wild-type CHO cells decreased the binding of the 125I-39-kd protein by approximately 40%, and the mutant CHO cells lacking HSPG bound half as much 125I-39-kd protein as wild-type CHO cells.(ABSTRACT TRUNCATED AT 250 WORDS)
牛乳铁蛋白可抑制血浆中残余脂蛋白的清除,并与富含载脂蛋白(apo)E的残余物的细胞表面结合相互竞争。我们证实,乳铁蛋白通过与硫酸乙酰肝素蛋白聚糖(HSPG)和低密度脂蛋白受体相关蛋白(LRP)相互作用来抑制残余物的结合和摄取。在用肝素酶处理以去除HSPG的HepG2肝细胞和野生型中国仓鼠卵巢(CHO)细胞中,125I-乳铁蛋白的结合被抑制了45%至60%。在缺乏HSPG的突变型CHO细胞(pgsD-677)中,125I-乳铁蛋白的结合水平约为野生型CHO细胞的50%;因此,约一半的乳铁蛋白结合似乎是通过细胞表面HSPG介导的。乳铁蛋白残余结合的很大一部分似乎是通过LRP介导的。已知与LRP结合并阻断配体相互作用的39-kd蛋白可使野生型CHO细胞中125I-乳铁蛋白的降解抑制60%至65%。添加39-kd蛋白并进行肝素酶处理可使结合减少85%至90%(这种组合可阻断与LRP和HSPG的直接相互作用)。然而,研究还表明,39-kd蛋白可与HSPG和LRP结合。用肝素酶处理野生型CHO细胞可使125I-39-kd蛋白的结合减少约40%,而缺乏HSPG的突变型CHO细胞结合的125I-39-kd蛋白量仅为野生型CHO细胞的一半。(摘要截短于250字)